Short answer: yes. An oromucosal medicine containing delta-9-tetrahydrocannabinol (THC) can produce a THC-positive result, but the meaning of that result depends on the specimen, the analyte measured, the collection time, and the testing method. A positive result is not a self-interpreting fact.
Nabiximols, marketed in some jurisdictions as Sativex®, contains THC and cannabidiol (CBD) in an approximately 1:1 ratio and is delivered as an oromucosal spray. Molnar and Fu reviewed the bioanalysis of the medicine, its metabolites, and related compounds in blood, urine, oral fluid, and hair. Their central forensic point is practical: medicinal cannabinoid exposure can complicate the interpretation of tests used in workplace, roadside, clinical, and sports settings.
The presence of a prescribed source changes the source-attribution question. It does not make the analytical result disappear, and it does not automatically establish impairment, misuse, or noncompliance.
Blood can contain parent THC, active 11-hydroxy-THC, and inactive 11-nor-9-carboxy-THC. It is generally more temporally informative than urine, but concentration alone still does not identify a precise dose, route, or degree of impairment. The review also notes that THC may persist in chronic users and that redistribution from tissue stores can complicate interpretation.
Routine urine testing commonly targets the carboxy metabolite THC-COOH. That makes urine useful for documenting prior exposure over a comparatively broad window, not for establishing current impairment. Hydration changes concentration, and the review discusses creatinine normalization as one way to address dilution. Even then, a urine result does not become a clock.
Oral-fluid testing often targets parent THC and can reflect recent exposure. An oromucosal spray creates a special interpretive issue because the medicine is applied in the mouth. Local deposition may contribute to a result, so collection timing and the device’s target and cutoff matter. A screen should not be confused with a fully specific confirmatory measurement.
Hair offers a longer retrospective window but brings questions about external contamination, incorporation, cosmetic treatment, and segment interpretation. It is not a reliable tool for deciding whether a person was impaired at a particular moment.
Immunoassay screens are designed to sort specimens efficiently. They may target a metabolite rather than the parent drug, and cross-reactivity and cutoff choices affect the result. Confirmatory methods such as liquid chromatography-tandem mass spectrometry can identify and quantify specific cannabinoids and metabolites. A defensible opinion should identify which step produced the reported finding.
A THC-positive result after use of a prescription oromucosal spray may be analytically expected. The proper interpretation is matrix-specific. Urine most directly supports prior exposure; oral fluid may be strongly affected by recent oral dosing; blood requires careful pharmacokinetic context; and hair is a retrospective exposure matrix. None of those findings, standing alone, proves impairment at a legally relevant time.
Source: Molnar A, Fu S. “Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds.” PubMed PMID 27005853.
This article is educational and does not provide medical or legal advice.